Cimetidine (Ulmet)
Cimetidine
Merck Generics Rsa (Pty) Ltd
Registration
- Applicant
- Merck Generics Rsa (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Ulmet 200 EACH TABLET CONTAINS CIMETIDINE 200 mg | 200 | Y0405Y/11.4.3/405 | Registered | Not determined | None |
| Ulmet 400 * EACH TABLET CONTAINS CIMETIDINE 400 mg | 400 | Y0406Y/11.4.3/406 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S3: Cimetidine
- except when intended for the short-term symptomatic relief of heartburn, dyspepsia and hyperacidity, subject to a maximum unit dose of 200 milligrams, a maximum daily dose (per 24 hours) of 800 milligrams and a maximum treatment period of 2 weeks. (S2)
Consolidated Schedules 06 July 2026, lines 3332 to 3334
S2: Cimetidine
- when intended for the short-term symptomatic relief of heartburn, dyspepsia and hyperacidity, subject to a maximum unit dose of 200 milligrams, a maximum daily dose of 800 milligrams and a maximum treatment period of 2 weeks. (S3)
Consolidated Schedules 06 July 2026, lines 1740 to 1742
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
1-Cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine
Drag to rotate. Structure from PubChem CID 2756.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.